Global Hypercalcemia Treatment Market – Industry Trends and Forecast to 2030

Hypercalcemia Treatment Market Analysis and Size

The increase in the geriatric globally is escalating the growth of the hypercalcemia treatment market. Hypercalcemia refers to a condition when calcium levels within the body increases rise with the serum calcium level that is greater than 2.6 mmol/L. This condition results in various problems such as weak bones and kidney stones. The treatment includes drugs or surgical removal of the overactive glands. To the access level of blood calcium, blood tests are also being done.  The rise in the number of cancer patients across the globe acts as one of the major factors driving the growth of hypercalcemia treatment market. The increase in the number of incidences of hypercalcemia among the population and the advent of new technology for the treatment for treating the disease accelerate the market growth.

Data Bridge Market Research analyses that the hypercalcemia treatment market which was USD 13,628.90 million in 2022, is expected to reach up to USD 33,854.70 million by 2030, and is expected to undergo a CAGR of 9.5% during the forecast period. This indicates that the market value. “Bisphosphonates” dominates the drug class segment of the global hypercalcemia treatment market owing to the rising incidences of cancer and other related issues. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hypercalcemia Treatment Market Scope and Segmentation

Market Definition

The term "hypercalcemia treatment" refers to medical procedures and regimens intended to lower and restore normal blood calcium levels (hypercalcemia). A serum calcium level of more than 10.4 mg/dL is commonly considered to be hypercalcemia, a medical disorder marked by an excess of calcium ions in the blood. While relieving symptoms, the main objective of hypercalcemia treatment is to address the underlying cause of the excessive calcium levels.

Global Hypercalcemia Treatment Market Dynamics

Drivers

• Increasing Prevalence of Hypercalcemia

Hypercalcemia is a medical condition characterized by elevated levels of calcium in the blood. The rising incidence of hypercalcemia due to various underlying medical conditions, such as primary hyperparathyroidism, cancer, and kidney disease, is a significant driver for the hypercalcemia treatment market.

• Rising Geriatric Population

The global aging population is more susceptible to conditions such as hypercalcemia. As the elderly population grows, the demand for hypercalcemia treatment is likely to increase.

Opportunities

• Increasing Awareness Regarding Hypercalcemia

Increasing awareness among healthcare professionals and patients about hypercalcemia and its treatment options can contribute to early diagnosis and treatment.

• Increasing Technological Advancements

Improved diagnostic tools and techniques enable early detection of hypercalcemia, which can lead to early treatment and a higher demand for therapeutic options. Ongoing research and development efforts in the pharmaceutical industry are likely to lead to the introduction of new and more effective treatment options for hypercalcemia.

Restrains/Challenges

• Strict Regulations and Guidelines

The approval and regulation of drugs for hypercalcemia treatment can be complex, as these drugs may also be used for other medical conditions. Navigating regulatory processes and obtaining approvals can be time-consuming and costly for pharmaceutical companies.

• High Cost of Equipment

Depending on the underlying cause of hypercalcemia and the required treatment, the cost of managing the condition can be significant. This can be a barrier to access to treatment, particularly in regions with limited healthcare resources.

• Limited Treatment Options

There were limited treatment options specifically approved for hypercalcemia. Bisphosphonates and calcimimetics were commonly used, but more targeted therapies for specific underlying causes were needed.

This hypercalcemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypercalcemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypercalcemia Treatment Market Scope

The hypercalcemia treatment market is segmented on the basis of drug class, distribution channel, application, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Drug Class

• Bisphosphonates
• Calcimimetic Agents
• Calcitonin
• Denusomab
• Glucocorticoids
• Pipeline Analysis

Application

• Mild Hypercalcemia
• Moderate Hypercalcemia
• Severe Hypercalcemia

End-Users

• Hospitals
• Clinics

Distribution Channel

• Direct Tenders
• Retail

Global Hypercalcemia Treatment Market Regional Analysis/Insights

The hypercalcemia treatment market is analyzed and market size insights and trends are provided by drug class, distribution channel, application, and end-user as referenced above.      

The countries covered in the hypercalcemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hypercalcemia treatment market because of the increase in the prevalence of hyperthyroidism within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in its awareness in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.      

Competitive Landscape and Hypercalcemia Treatment Market Share Analysis

The hypercalcemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related hypercalcemia treatment market.

Some of the major players operating in the hypercalcemia treatment market are:

• Fujirebio (Japan)
• DIASORIN S.p.A (Italy)
• Mylan N.V. (U.S.)
• Dr. Reddy’s Laboratories Ltd (India)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)
• Sun Pharmaceutical Industries Ltd (U.S.)
• Kyowa Kirin Co. Ltd. (Japan)
• Cipla Inc. (India)
• Bayer AG (Switzerland)
• Pfizer Inc. (U.S.)
• OPKO Health, Inc. (U.S.)
• Rockwell Medical (U.S.)
• Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
• Fortis Healthcare (India)
• Sanofi-aventis U.S. LLC (France)
• Aetna Inc. (U.S.)
• AstraZeneca (U.K.)
• A6 Pharmaceuticals (U.S.)
• Johnson & Johnson Services, Inc. (U.S.) 

SKU-10607